METHOD / EDITORIAL STANDARD
Evidence Is Sorted Before It Is Summarized
AV Peptide is an independent reading desk for mechanisms, biomarkers, tissue outcomes, and the boundaries between them.
What this desk measures
AV Peptide is an independent editorial digest covering four compounds adjacent to Growth Hormone Axis research: MOTS-c, CJC-1295, tesamorelin, and ipamorelin. The site is built around a problem that recurs in endocrine writing: a measured hormone change is often presented as if it were a measured health benefit. The two are not interchangeable.
Every compound page therefore separates mechanism, pharmacokinetics, pharmacodynamics, tissue outcomes, clinical outcomes, safety evidence, and anecdotal reports. A receptor response explains that a biological pathway moved. GH and IGF-1 concentrations quantify part of that movement. Body-composition imaging measures a tissue compartment. A controlled trial tests a prespecified hypothesis. Each layer is useful, and each has a different inferential reach.
The collection is intentionally heterogeneous. MOTS-c supplies mitochondrial and preclinical biology. CJC-1295 supplies sustained human GH/IGF-1 pharmacology. Tesamorelin supplies randomized body-composition evidence in a narrow approved setting. Ipamorelin supplies acute human modeling and a negative primary efficacy result. Reading those files together makes evidence maturity visible.
How the analysis is built
The source base is a composed, citation-audited corpus. Each quantitative statement in the editorial pages is attached to a numbered reference. Reference entries preserve the source title, authors, journal, year, and available persistent identifiers. The prose does not invent studies, convert model findings into human findings, or treat a review as though it were a randomized trial.
The analysis uses four recurring questions. What was exposed? Endogenous circulating MOTS-c is not external MOTS-c, and CJC-1295 DAC is not the same duration as a no-DAC form. Who or what was studied? Cells, rodents, ferrets, healthy volunteers, surgical patients, and adults with HIV-associated lipodystrophy support different claims. What was measured? A GH pulse, IGF-1 concentration, imaging-derived fat compartment, tolerated meal, and cardiovascular event are not equivalent endpoints. What was the comparator? An uncontrolled observation and a randomized placebo comparison carry different protection against bias.
Anecdotal material is retained only when the supplied corpus contains it, and it is explicitly marked “anecdotal, not clinical evidence.” Such reports can map recurring questions; they cannot establish efficacy, incidence, or causation.
Editorial boundaries
AV Peptide is not a clinic, pharmacy, laboratory supplier, or prescribing service. Nothing is sold, sourced, endorsed, or ranked for personal use. Study exposures may be described to explain published research, but no personal dose, schedule, route, or combination protocol is provided. Requests for individual interpretation belong in a licensed clinical relationship.
Regulatory status is kept compound-specific. Tesamorelin has a defined prescription indication in HIV-associated lipodystrophy. The other compounds in this collection do not acquire that status by sharing a page or a signaling theme. Research-grade material does not acquire pharmaceutical quality because a similarly named molecule appeared in a paper.
Corrections are part of the method. The contact desk accepts precise notes about a page, statement, or reference. The references page is the common audit trail, and the comparison shows where evidence categories diverge. The aim is not to make every compound sound equally promising. It is to make the strength and boundary of every claim easy to inspect.